Novartis plots 'next frontier' of MS treatment — and it could spell a buyout for a small Swiss player
A couple of months after getting its self-administered multiple sclerosis drug Kesimpta cleared by EU regulators, Novartis has found what it believes is “the next …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
